patrick.net
An Antidote to Corporate Media
1,189,915 comments by 13,850 users - PeopleUnited, RC2006, Stout, UkraineIsTotallyFucked online now
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
invite response
2021 Sep 5, 4:05am 188 views 1 comment
Comments 1 - 1 of 1 Search these comments
1
Patrick
2021 Sep 5, 10:08am
Patrick
2021 Sep 5, 10:08am
How obvious does it have to be that Ivermectin works until the NIH approves it so that hospitals can keep their liability protection when using it?
https://patrick.net/post/1341005/2021-09-01-hospitals-refuse-to-prescribe-ivermectin
Clearly the reasons it is not approved are NIH corruption on an intergalactic scale for the benefit of Big Pharma, and to keep the crisis going as long as possible so that government suppression of civil liberties can be permanently cemented into place.
Even if they reject the overwhelming evidence that it is effective, how can they still forbid hospitals from using it when they know it's extremely safe? Shouldn't it be up to individual doctors to try one of the safest drugs ever on their patients?
https://patrick.net/post/1341005/2021-09-01-hospitals-refuse-to-prescribe-ivermectin
Clearly the reasons it is not approved are NIH corruption on an intergalactic scale for the benefit of Big Pharma, and to keep the crisis going as long as possible so that government suppression of civil liberties can be permanently cemented into place.
Even if they reject the overwhelming evidence that it is effective, how can they still forbid hospitals from using it when they know it's extremely safe? Shouldn't it be up to individual doctors to try one of the safest drugs ever on their patients?
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.
https://pubmed.ncbi.nlm.nih.gov/34466270/